AFDX0250 Aqueous Packaging and Filtration for Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

AFDX0250, a compound used for treating eye diseases, is unstable in aqueous pharmaceutical compositions due to hydrolysis and degradation under light exposure, leading to the production of degradation products, which affects the stability and safety of the preparation.

Innovation Solution

Storing the aqueous pharmaceutical composition of AFDX0250 or its salt in a package that blocks light wavelengths between 210 to 380 nm, particularly 216 to 310 nm and 372 nm, and using plastic containers such as polyethylene, polypropylene, or polyethylene terephthalate containers, along with sterilization by filtration, to inhibit degradation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Ease of operation

If AFDX0250 is dissolved in aqueous solution to prepare pharmaceutical composition, then the compound can be administered in liquid form, but the compound is easily hydrolyzed and degraded, producing degradation products

Engineering Contradiction:

Improveliquid form administrationVSAvoidcompound stability

Core Design Contradiction:

Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent applies parameter changes by adjusting the pH value of the aqueous pharmaceutical composition to specific ranges (pH 3.0-6.0 for AFDX0250, pH 4.0-7.0 for its salt) to suppress hydrolysis and degradation reactions, thereby maintaining compound stability in liquid form

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces specific packaging materials as intermediaries that block ultraviolet light (particularly wavelengths of 216 nm and 310 nm) to prevent photodegradation of the compound, while allowing the composition to remain in stable aqueous form

Inventive Principle:

Principle #24Intermediary (Mediator)

2Duration of action of stationary object

If conventional packaging is used for aqueous pharmaceutical composition, then the preparation can be stored, but light exposure causes degradation of AFDX0250 and production of degradation products

Engineering Contradiction:

Improvestorage durationVSAvoidlight-induced degradation

Core Design Contradiction:

Duration of action of stationary objectVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by designing packaging with specific UV-blocking properties at critical wavelengths (216 nm and 310 nm) while maintaining transparency or visibility at other wavelengths, providing selective protection where needed

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs composite packaging structures combining materials with complementary properties to achieve both UV protection and aesthetic/appraisal functions, such as combining UV-blocking layers with transparent containers

Inventive Principle:

Principle #40Composite materials

3Reliability

If sterilization methods other than filtration are used, then sterilization efficiency may be higher, but hydrolysis and degradation of the compound are accelerated

Engineering Contradiction:

Improvesterilization effectivenessVSAvoidcompound stability during sterilization

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent replaces thermal sterilization methods (autoclaving) with membrane filtration as a mechanical separation process that achieves sterilization without exposing the compound to high temperatures that would accelerate hydrolysis and degradation

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the sterilization parameter from thermal treatment to physical filtration, maintaining sterilization effectiveness while preserving compound stability by avoiding temperature-induced degradation

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Improves the thermal and photostability of AFDX0250, maintaining its stability and safety in the composition, reducing the production of hydrolysates and degradation products, thus ensuring long-term storage and effectiveness.

Implementation Method 1

the storage of an aqueous pharmaceutical composition comprising AFDX0250 or a salt thereof in a package which blocks a light having a wavelength of from 210 to 380 nm

Methodology Applied

Scientific EffectLight blocking/UV absorption: Absorption (EM radiation)

Implementation Method 2

AFDX0250 is easily hydrolyzed and the hydrolysate of AFDX0250, 5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one is easily precipitated

Methodology Applied

Scientific EffectHydrolysis prevention: Hydrolysis

Data Source

PatentUS20250213588A1Sterilization method of pharmaceutical preparation and packaging

Publication Date: 2025.07.03 SANTEN PHARMACEUTICAL CO LTD

AI summary

The present invention provides a pharmaceutical preparation comprising an aqueous pharmaceutical composition comprising (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, wherein the aqueous pharmaceutical composition is stored in a package which blocks a light having a wavelength of from 210 to 380 nm, in which the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or the salt thereof in the aqueous pharmaceutical composition is improved.